{"id":915159,"date":"2025-12-02T10:28:57","date_gmt":"2025-12-02T15:28:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/"},"modified":"2025-12-02T10:28:57","modified_gmt":"2025-12-02T15:28:57","slug":"doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/","title":{"rendered":"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio"},"content":{"rendered":"

\nDNA-based Colorectal Cancer Screening as a Home Test
\n<\/h2>\n
\n

BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V.<\/u><\/a> (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201c), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert\u00ae has been added to the portfolio of DoctorBox, one of Germany\u2019s leading pioneers in digital health. This marks another important milestone in Mainz Biomed\u2019s European growth strategy and highlights the increasing importance of innovative, personalized solutions in preventive medicine. Laboratory analysis will be performed by Mainz Biomed\u2019s long-standing partner, the European Oncology Lab, led by Dr. med. Annette Buhlmann in St. Ingbert, Germany.<\/p>\n

Colorectal cancer is one of the most common yet preventable cancers worldwide. In Germany alone, around 60,000 new cases are diagnosed each year \u2014 a clear indicator of the need for highly effective early detection measures. By integrating Mainz Biomed\u2019s advanced DNA diagnostics into DoctorBox\u2019s digital healthcare platform, this collaboration establishes a highly innovative model of care that can significantly expand access to ColoAlert.<\/p>\n

\u201cWith DoctorBox, we are gaining a strong partner that enables us to offer ColoAlert exactly where prevention can take place today \u2014 at home,\u201d said Guido Baechler, CEO of Mainz Biomed. \u201cTogether, we are lowering barriers to colorectal cancer screening and providing easy access to DNA-based early detection.\u201d<\/p>\n

\u201cColoAlert fits perfectly into our portfolio of next-generation DNA- and RNA-based tests. Thus, innovative colorectal cancer screening becomes another cornerstone of our digital preventive healthcare platform,\u201d said Julian Maar, CEO of DoctorBox.<\/p>\n

The DoctorBox app brings together modern preventive healthcare services on a single platform: with over one million registered users and more than ten million test results transmitted, DoctorBox ranks among Europe\u2019s leading digital prevention solutions. The offering includes guideline-based preventive-care reminders \u2013 personalized by age, sex, and risk profile. Additional services include at-home tests and locally accessible diagnostics, for example for early detection of colorectal, cervical, and prostate cancer (self-pay or reimbursed). Measures for sexual health, allergies, as well as innovative analyses, digital evaluation and support \u2013 including the delivery of findings, recommendations for action, and video consultations directly within the app \u2013 are also part of the DoctorBox offering.<\/p>\n

\n
\n Please visit Mainz Biomed\u2019s official website for investors at mainzbiomed.com\/investors\/ for more information <\/strong>
\n <\/a>\n <\/p>\n

Please follow us to stay up to date:
LinkedIn<\/strong><\/a>
X (Previously Twitter)<\/strong><\/a>
Facebook<\/strong><\/a><\/p>\n

\n About DoctorBox<\/strong>
\n
DoctorBox is setting the new standard for prevention in Europe \u2014 made in Germany.
As one of Germany\u2019s leading digital solutions for smart preventive healthcare, DoctorBox empowers more than one million users in Germany and other European countries to manage their health prevention easily, digitally, and independently. Whether through reminders, at-home tests, or local diagnostics, DoctorBox makes preventive healthcare accessible and part of everyday life.
To learn more, visit doctorbox.de<\/strong>.<\/strong><\/p>\n

\n About Mainz Biomed NV<\/strong>
\n
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company\u2019s flagship product is ColoAlert\u00ae, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert\u00ae is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed\u2019s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples.<\/p>\n

To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.<\/strong><\/p>\n

\n For media inquiries<\/strong>
\n
MC Services AG
Maximilian Schur \/ Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu<\/a>
For investor inquiries, please contact\u00a0<\/strong>ir@mainzbiomed.com<\/strong><\/a><\/p>\n

\n Forward-Looking Statements<\/strong>
\n
Certain statements made in this press release are \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201cestimate\u201d, \u201cplan\u201d, \u201coutlook\u201d, and \u201cproject\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company\u2019s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the \u201cSEC\u201d) by the Company. Additional information concerning these and other factors that may impact the Company\u2019s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company\u2019s SEC filings are available publicly on the SEC\u2019s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

DNA-based Colorectal Cancer Screening as a Home Test BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201c), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert\u00ae has been added to the portfolio of DoctorBox, one of Germany\u2019s leading pioneers in digital health. This marks another important milestone in Mainz Biomed\u2019s European growth strategy and highlights the increasing importance of innovative, personalized solutions in preventive medicine. Laboratory analysis will be performed by Mainz Biomed\u2019s long-standing partner, the European Oncology Lab, led by Dr. med. Annette Buhlmann in St. Ingbert, Germany. Colorectal cancer is one of the most common yet preventable cancers worldwide. … <\/p>\n

Continue reading “DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915159","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DNA-based Colorectal Cancer Screening as a Home Test BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201c), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert\u00ae has been added to the portfolio of DoctorBox, one of Germany\u2019s leading pioneers in digital health. This marks another important milestone in Mainz Biomed\u2019s European growth strategy and highlights the increasing importance of innovative, personalized solutions in preventive medicine. Laboratory analysis will be performed by Mainz Biomed\u2019s long-standing partner, the European Oncology Lab, led by Dr. med. Annette Buhlmann in St. Ingbert, Germany. Colorectal cancer is one of the most common yet preventable cancers worldwide. … Continue reading "DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T15:28:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MjE0MyM0MDIyNzQ3NzAjMjIyNDA4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio\",\"datePublished\":\"2025-12-02T15:28:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/\"},\"wordCount\":939,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0MjE0MyM0MDIyNzQ3NzAjMjIyNDA4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/\",\"name\":\"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0MjE0MyM0MDIyNzQ3NzAjMjIyNDA4OQ==\",\"datePublished\":\"2025-12-02T15:28:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0MjE0MyM0MDIyNzQ3NzAjMjIyNDA4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0MjE0MyM0MDIyNzQ3NzAjMjIyNDA4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio - Market Newsdesk","og_description":"DNA-based Colorectal Cancer Screening as a Home Test BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201c), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert\u00ae has been added to the portfolio of DoctorBox, one of Germany\u2019s leading pioneers in digital health. This marks another important milestone in Mainz Biomed\u2019s European growth strategy and highlights the increasing importance of innovative, personalized solutions in preventive medicine. Laboratory analysis will be performed by Mainz Biomed\u2019s long-standing partner, the European Oncology Lab, led by Dr. med. Annette Buhlmann in St. Ingbert, Germany. Colorectal cancer is one of the most common yet preventable cancers worldwide. … Continue reading \"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-02T15:28:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MjE0MyM0MDIyNzQ3NzAjMjIyNDA4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio","datePublished":"2025-12-02T15:28:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/"},"wordCount":939,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MjE0MyM0MDIyNzQ3NzAjMjIyNDA4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/","name":"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MjE0MyM0MDIyNzQ3NzAjMjIyNDA4OQ==","datePublished":"2025-12-02T15:28:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MjE0MyM0MDIyNzQ3NzAjMjIyNDA4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MjE0MyM0MDIyNzQ3NzAjMjIyNDA4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/doctorbox-adds-mainz-biomeds-coloalertr-to-its-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DoctorBox Adds Mainz Biomed\u2019s ColoAlert(R) to Its Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915159"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915159\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}